Market Overview

UPDATE: Piper Jaffray Initiates Galena Biopharma at Overweight on ImmunoRx Potential

Related GALE
Galena Biopharma Presents GALE-401 (Anagrelide Controlled Release) Clinical Trial Data At The 56th American Society of
UPDATE: MLV & Co Reiterates On Galena Biopharma As External Risks Have Subsided

Piper Jaffray initiated coverage on Galena Biopharma (NASDAQ: GALE) with an Overweight rating and a $2.50 price target.

Piper Jaffray commented, "Galena is a cancer immunotherapy company that is developing NeuVax, which could be a new blockbuster breast cancer adjuvant therapy. Galena should complete enrollment of the Phase III PRESENT trial this summer with 36-month Disease Free Survival (DFS) data in mid-2016. Galena is also developing a Folate Binding Protein E39 (FBP-E39) targeted vaccine in a Phase I/II ovarian and endometrial cancer trial with preliminary data at ASCO in June. We look for clinical progress and potential partnerships to drive shareholder value in 2013. Galena recently raised $24 million, which should fund the company into 2014."

Galena Biopharma closed at $1.55 on Friday.

Latest Ratings for GALE

DateFirmActionFromTo
Nov 2014MLV & Co.ReiteratesBuy
Nov 2014Cantor FitzgeraldMaintainsSell
Mar 2014McNicoll Lewis VlakMaintainsBuy

View More Analyst Ratings for GALE
View the Latest Analyst Ratings

Posted-In: Piper JaffrayAnalyst Color Initiation Pre-Market Outlook Analyst Ratings

 

Related Articles (GALE)

Around the Web, We're Loving...

Get Benzinga's Newsletters